Our focus is on late-stage product development, leveraging efficient regulatory pathways to bring products to market. Additionally, all products introduced by Arbor incorporate novel child-centric features to enhance the therapeutic utility and clinical benefit to the patient. This approach has yielded and will continue to yield a robust pipeline of products that are well positioned for the pediatric market.

The therapeutic focus of Arbor is closely aligned with the most common childhood illnesses. Specifically, the company’s initial commercialization and product development efforts have been primarily focused on products for common ear infections. The company has identified and is progressing other product candidates for significant common pediatric illnesses.